{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:09:04Z","timestamp":1777536544798,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.urolonc.2021.02.020","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T03:57:49Z","timestamp":1616471869000},"page":"631-641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?"],"prefix":"10.1016","volume":"39","author":[{"given":"Giuseppe","family":"Basile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pederzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2021.02.020_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.02.020_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.02.020_bib0003","article-title":"Intravesical bacillus Calmette-Guerinreduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"RJ","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.02.020_bib0004","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"maintenance bacillus calmette-guerin immunotherapy for recurrent ta, t1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"j urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.02.020_bib0005","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clgc.2016.06.014","article-title":"Association between number of endoscopic resections and utilization of bacillus Calmette-Gu\u00e9rin therapy for patients with high-grade, non\u2013muscle-invasive bladder cancer","volume":"15","author":"Lenis","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2021.02.020_bib0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.02.020_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2021.02.020_bib0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic implication of the United States food and drug administration-defined BCG-unresponsive disease [Figure presented]","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2021.02.020_bib0009","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.02.020_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eururo.2019.08.011","article-title":"Improving estimates of perioperative morbidity after radical cystectomy using the European association of urology quality criteria for standardized reporting and introducing the comprehensive complication index[Formula presented]","volume":"77","author":"Vetterlein","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0011","article-title":"Neoadjuvant chemotherapy or immunotherapy for clinical T2N0 muscle-invasive bladder cancer: time to change the paradigm?","author":"Pederzoli","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"0","key":"10.1016\/j.urolonc.2021.02.020_bib0012","article-title":"Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder","volume":"0","author":"Rouanne","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.02.020_bib0013","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.euo.2019.01.002","article-title":"Effect of immunotherapy on local treatment of genitourinary malignancies","volume":"2","author":"Pignot","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"10122","key":"10.1016\/j.urolonc.2021.02.020_bib0014","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.urolonc.2021.02.020_bib0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.02.020_bib0016","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2021.02.020_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.02.020_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10236","key":"10.1016\/j.urolonc.2021.02.020_bib0019","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4590","article-title":"Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"issue":"0","key":"10.1016\/j.urolonc.2021.02.020_bib0021","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"0","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl_4","key":"10.1016\/j.urolonc.2021.02.020_bib0022","first-page":"31","article-title":"Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361","author":"Alva","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0023","year":"2020"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.02.020_bib0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2021.02.020_bib0026","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.4049\/jimmunol.160.12.6188","article-title":"An antigen recognized by autologous CTLs on a human bladder carcinoma","volume":"160","author":"Gu\u00e9guen","year":"1998","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.urolonc.2021.02.020_bib0027","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.urolonc.2021.02.020_bib0028","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.urolonc.2021.02.020_bib0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2021.02.020_bib0031","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"75","key":"10.1016\/j.urolonc.2021.02.020_bib0032","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5041","article-title":"Pembrolizumab (pembro)for the treatment of patients with Bacillus Calmette-Gu\u00e9rin (BCG) unresponsive, high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC): over two years follow-up of KEYNOTE-057","volume":"38","author":"Balar","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0035","series-title":"FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer | FDA","year":"2020"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"38","author":"Black","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.02.020_bib0037","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.2217\/fon-2019-0611","article-title":"ENERGIZE: a phase III study of neoadjuvant chemotherapy alone or with nivolumab with\/without linrodostat mesylate for muscle-invasive bladder cancer","volume":"16","author":"Sonpavde","year":"2019","journal-title":"Futur Oncol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4503","article-title":"Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","volume":"35","author":"Smith","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2021.02.020_bib0039","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2021.02.020_bib0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.21873\/anticanres.11458","article-title":"Expression of indoleamine 2,3-dioxygenase gene is a feature of poorly differentiated non-muscle-invasive urothelial cell bladder carcinomas","volume":"37","author":"Hudolin","year":"2017","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2021.02.020_bib0041","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer","volume":"63","author":"Prendergast","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.urolonc.2021.02.020_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/s41585-020-00379-4","article-title":"Targetable gene fusions and aberrations in genitourinary oncology","volume":"17","author":"Pederzoli","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0043","article-title":"Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study","author":"Necchi","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2021.02.020_bib0044","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2021.02.020_bib0045","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.4049\/jimmunol.170.10.5018","article-title":"IL-15 Promotes the survival of naive and memory phenotype CD8\u202f+\u202fT cells","volume":"170","author":"Berard","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.02.020_bib0046","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 trans -signaling with the superagonist RLI promotes effector\/memory CD8\u202f+\u202fT cell responses and enhances antitumor activity of PD-1 antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J Immunol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0047","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4561","article-title":"Soon-shiong P. preliminary phase 2 clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients","volume":"37","author":"Chamie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0048","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1097\/JU.0000000000000823.02","article-title":"PD03-02 Phase 3 results of vicinium in BCG-unresponsive non-muscle invasive bladder cancer","volume":"203","author":"Shore*","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0049","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1016\/S2666-1683(20)33377-2","article-title":"Results of a phase II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Gu\u00e9rin (BCG) VPM1002BC in patients with BCG failure - SAKK 06\/14","volume":"19","author":"Rentsch","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2021.02.020_bib0050","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0051","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0000556225.57786.36","article-title":"MP43-02 CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (nmibc): 18 month follow-up from a multicenter phase ii trial","volume":"201","author":"Packiam*","year":"2019","journal-title":"J Urol"},{"issue":"30","key":"10.1016\/j.urolonc.2021.02.020_bib0052","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd\u2013IFNa\/Syn3 for patients with high-grade, bacillus calmette-guerin\u2013refractory or relapsed non\u2013muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.02.020_bib0053","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","author":"Boorjian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.02.020_bib0054","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical bacillus calmette guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients","volume":"23","author":"Derr\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.urolonc.2021.02.020_bib0055","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00262-018-2197-x","article-title":"Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette\u2013Guerin for patients with non-muscle invasive bladder cancer","volume":"67","author":"Obara","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.urolonc.2021.02.020_bib0056","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10637-018-00716-w","article-title":"Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer","volume":"37","author":"Zahoor","year":"2019","journal-title":"Invest New Drugs"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2021.02.020_bib0057","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.7_suppl.293","article-title":"Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC)","volume":"33","author":"Helfand","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:53Z","timestamp":1761042233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1078143921000818"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.02.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}